Pfizer India cooperates in Karnataka counterfeit-medicines probe
Pfizer India said it has withdrawn affected genuine batches and is working with Karnataka authorities after raids near Bengaluru uncovered alleged repacking and sale of spurious medicines under its brand. Regulators cancelled 16 drug licences and suspended eight.
What happened
Pfizer India is cooperating with Karnataka authorities probing counterfeit medicines allegedly repacked and sold under its brand. The company removed affected
Key facts
- 16 drug licences cancelled
- 8 drug licences suspended
- ₹5.05 crore worth of spurious drugs, machinery and printing materials seized
- August 18 inspection
- Drugs and Cosmetics Act, 1940
Why this matters
Any India healthcare partnership or acquisition diligence should prioritize supply-chain controls, licence compliance and anti-counterfeit capabilities following the Karnataka enforcement action.
What to watch
- Whether raids identify additional Pfizer brands, batch numbers, therapeutic categories or states.
- Announcements of further licence cancellations, criminal charges, distributor blacklisting or nationwide regulatory advisories.
- Scope of Pfizer batch withdrawals and whether the company reports supply interruptions or expanded field actions.
- Reports of adverse patient events, treatment failures or social-media concern tied to suspected products.
- Central Drugs Standard Control Organisation involvement or mandated serialization/authentication measures.
- Changes in pharmacy procurement behavior, especially demand shifting toward large authorized chains and hospital pharmacies.
- Expand distributor, stockist and pharmacy audits in Karnataka and potentially adjacent southern states.
- Use batch-level traceability, targeted withdrawals and retailer communication to distinguish genuine stock from suspected counterfeit products.
- Coordinate with Karnataka drug-control authorities on evidence, consumer warnings and prosecution support.
- Review authorized-channel controls, returns handling, repacking exposure and high-risk product diversion points.
- Increase pharmacist and patient education on packaging, batch verification and authorized purchase channels.